Rasilez Now Approved in China

Basel, July 20, 2010 - RasilezĀ® (aliskiren), a first-in-class direct renin inhibitor, has received regulatory approval in China for the treatment of high blood pressure alone or in combination with other high blood pressure medicines[9]. Rasilez blocks the activity of renin, an enzyme that triggers a process that may lead to high blood pressure[10].

Back to news